CVS Health Beats Second-Quarter Estimates as Aetna Stabilizes

The company now projects full-year adjusted profit between $7.90 and $8.10 per share, climbing from its earlier forecast of $7.30 to $7.50. Revenue targets for 2026 have also been bolstered to at least $414 billion. While all three core segments—insurance, pharmacy, and health services—topped analyst expectations, the recovery of Aetna remains the primary focus for investors wary of the rising medical costs that have plagued private Medicare plans for the past two years.

Management credits the improved outlook to operational efficiency, including a $2 billion cost-cutting initiative, store closures, and leadership changes. Despite the positive momentum, leadership maintains a conservative posture for the remainder of the year, citing broader macroeconomic risks. Alongside the financial results, CVS revealed a new partnership with Eli Lilly to distribute obesity treatments Zepbound and Foundayo through its digital app starting in the fourth quarter. The company’s net income reached $2.98 billion for the period, a significant jump from the $1.02 billion reported during the same quarter last year.